ArticleCureus2026
Extended-Interval Immunotherapy in Advanced Lung Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma frequently presents at an advanced stage with metastases, including the brain. Advances in immunotherapy have improved survival rates; however, challenges remain regarding optimal dosing schedules and the management of immune-related adverse events (irAEs). This case report aims to demonstrate that a less frequent immunotherapy regimen, administered every six weeks, in certain clinical scenarios may maintain durable disease stabilization while potentially reducing clinically significant toxicities. These findings support further evaluation of modified-dose immunotherapy regimens in clinical trials. We retrospectively reviewed the clinical course of a patient with advanced lung adenocarcinoma with brain and contralateral lung involvement over a 14-month period. The patient underwent biopsy confirmation, immunotherapy with atezolizumab, stereotactic radiosurgery for oligometastatic brain lesions, and subsequent therapeutic adjustments, including antibiotic treatment for pneumonia and immunotherapy regimen modifications to manage irAEs. The patient ultimately received a total of nine cycles of atezolizumab. Initial atezolizumab treatment (administered every three weeks) achieved disease stabilization (RECIST 1.1: -26.4%). The immunotherapy interval was adjusted to every six weeks during the treatment course to mitigate toxicities. Disease control was maintained with manageable irAEs, improving the patient's quality of life. This case supports the hypothesis that, in individualized cases, a six-week immunotherapy schedule could provide durable responses in advanced lung adenocarcinoma with fewer life-threatening irAEs. These findings could inform future trials to assess the broader applicability of extended immunotherapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.